BioXcel Therapeutics Announces Proposed Public Offering
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical…
0,448€
-2,61%
Echtzeit-Aktienkurs BioXcel Therapeutics Inc.
Bid:
Ask:
Nachrichten zur BioXcel Therapeutics Inc. Aktie
BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…
BioXcel Therapeutics Aktie: Kursanstieg trotz herausforderndem Marktumfeld
BioXcel Therapeutics verzeichnete am 14. September 2024 einen Kursanstieg von 1,64% auf 0,62 EUR. Dies markiert eine positive Entwicklung für…
BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript
…
BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript
…
BioXcel Therapeutics secures $25 million in direct offering By Investing.com
BioXcel Therapeutics secures $25 million in direct offering…
BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript
…
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…
BioXcel Therapeutics Announces Termination of Proposed Public Offering
NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…
BioXcel Therapeutics surges on FDA fast track designation for BXCL701 By Investing.com
BioXcel Therapeutics surges on FDA fast track designation for BXCL701…
BIOXCEL ALERT: Bragar Eagel & Squire, P.C. is Investigating BioXcel Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
BioXcel Therapeutics stock plummets as 3Q earnings fall short of expectations
BioXcel Therapeutics Inc (NASDAQ:BTAI) shares fell almost 35% after it reported a revenue miss and greater than forecast loss for…
BioXcel Therapeutics, Inc. (BTAI) Q3 2023 Earnings Call Transcript
…
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023
NEW HAVEN, Conn., Oct. 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…
BioXcel shares rally as audit confirms integrity of late-stage Alzheimer’s trial data
BioXcel Therapeutics Inc (NASDAQ:BTAI) shares rallied on Wednesday after the artificial intelligence (AI)-powered biopharmaceutical company reported that an...…
: BioXcel Therapeutics shares pop after audit of Alzheimer’s trial data
Audit findings support application for approval of treatment for Alzheimers-related agitation, company says…
BTAI: BXCL701 Shows Positive Overall Survival Results in Phase 2 Trial…
By John Vandermosten, CFA
NASDAQ:BTAI
READ THE FULL BTAI RESEARCH REPORT
Business Update
Positive Overall Survival Results Seen in Phase 2 Trial of BXCL701
On…
Investors in BioXcel Therapeutics, Inc. (NASDAQ: BTAI) should contact the Shareholders Foundation in connection with a Lawsuit
Investors, who lost money with shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI), should contact the Shareholders Foundation, Inc.…
Lifshitz Law PLLC Announces Investigations of ImmunityBio, Inc. (NASDAQ: IBRX), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Baxter International Inc. (NYSE: BAX)
NEW YORK, Sept. 30, 2023 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX)…
BioXcel Therapeutics: Kursziel gekürzt
Vancouver (www.aktiencheck.de) - Rating-Update:
Sumant Kulkarni, Analyst von Canaccord Genuity, stuft die Aktie des US-Biotechnologie-Unternehmens BioXcel Therapeutics Inc. (ISIN: US09075P1057, WKN:…
BioXcel Therapeutics: Kurszielsenkung
Charlotte, NC (www.aktiencheck.de) - Rating-Update:
Robyn Karnauskas, Analystin von Truist, stuft die Aktie des US-Biotechnologie-Unternehmens BioXcel Therapeutics Inc. (ISIN: US09075P1057, WKN:…
Mizuho cuts BioXcel to neutral, cites reduced expectations for lead drug
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Why BioXcel Therapeutics Stock Flopped Again Today
Major changes are afoot with the company, and few are happy about them....…
Truist reduces BioXcel Therapeutics price target to $31 from $71
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
XFRA : BX2: Wiederaufnahme/Resumption
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING…
XFRA : BX2: Aussetzung/Suspension
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME …
Why BioXcel Therapeutics Stock Is Getting Crushed Today
BioXcel just announced a big change....…
Form 10-Q BioXcel Therapeutics, For: Jun 30
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioXcel Therapeutics to cut workforce 58%, stock falls 27%
Shares of BioXcel Therapeutics BTAI tumbled 27% premarket on Monday as the biopharma company said it would cut its workforce…
BioXcel Shares Tumble 27% After Cutting Workforce
BioXcel Shares Tumble 27% After Cutting Workforce...…
BioXcel falls on plans for business reorganization
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioXcel Therapeutics to Cut Nearly 60% of Workforce
BioXcel Therapeutics to Cut Nearly 60% of Workforce...…
BioXcel announces job cuts to focus on agitation related treatment
...(Reuters) - BioXcel Therapeutics Inc said on Monday......…
UPDATE 1-BioXcel announces job cuts to focus on agitation related treatment
...(Adds details in paragraphs 2)
Aug 14 (Reuters) - BioXcel......…
XFRA : INSTRUMENT_SUSPENSION - US09075P1057
Instrument ID [8003] (BX2 - US09075P1057) suspended...…
Form 8-K BioXcel Therapeutics, For: Aug 14
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioXcel Therapeutics GAAP EPS of -$1.83 misses by $0.11, revenue of $0.46M misses by $0.01M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioXcel announces job cuts
...Aug 14 (Reuters) - BioXcel Therapeutics Inc
said on Monday......…
BioXcel Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023
NEW HAVEN, Conn., July 31, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing…
Why BioXcel Therapeutics Stock Was Bouncing Back This Week
What a difference a handful of trading days has made for the company....…
Why Shares of BioXcel Therapeutics Are Plunging Thursday
Questions regarding the safety of an Alzheimers disease agitation therapy were raised when the company announced phase 3 trial results....…
BioXcel Shares Hit 52-Week Low After Fraud Investigation Overshadows Trial Results
BioXcel Shares Hit 52-Week Low After Fraud Investigation Overshadows Trial Results...…
RenovoRx, Immunome top healthcare gainers; BioXcel, CorMedix among losers
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Pre-market Movers: Sigilon Therapeutics, Eco Wave Power, BioXcel Therapeutics, Kintara Therapeutics, CorMedix
WATERLOO (dpa-AFX) - The following are some of the stocks making big moves in Thursdays pre-market trading (as of 07.55…
BioXcel sheds 58% as data integrity issues cloud Alzheimer’s trial win
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
BioXcel Shares Drop Premarket Following Results for Phase 3 Trial of BXCL501
BioXcel Shares Drop Premarket Following Results for Phase 3 Trial of BXCL501...…
Insiderhandel: CEO and President verkauft Aktien von BioXcel Therapeutics im Wert von 646.226$
Mehta, Vimal - Vorstand - Tag der Transaktion: 2023-06-15...…
Insiderhandel: CEO and President verkauft Aktien von BioXcel Therapeutics im Wert von 605.501$
Mehta, Vimal - Vorstand - Tag der Transaktion: 2023-06-16...…
BioXcel Therapeutics: Hohe Kursschwankungen - Aktienanalyse
Kulmbach (www.aktiencheck.de) - BioXcel Therapeutics-Aktienanalyse von "Der Aktionär":
Jürgen Dreifürst vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…